## Paul I Dargan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4039873/publications.pdf

Version: 2024-02-01

235 papers

64,529 citations

59 h-index 219 g-index

238 all docs

238 docs citations

times ranked

238

85746 citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
4	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
5	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
6	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
7	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
8	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
9	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
10	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
11	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
12	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
13	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
14	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
15	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Injury Prevention, 2016, 22, 3-18.	2.4	898
16	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
17	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
18	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573

#	Article	IF	Citations
19	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
20	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
21	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
22	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
23	Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2257-2274.	13.7	279
24	Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology, 2010, 48, 924-927.	1.9	192
25	Global Mortality From Firearms, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 320, 792.	7.4	189
26	Outbreak of Fatal Childhood Lead Poisoning Related to Artisanal Gold Mining in Northwestern Nigeria, 2010. Environmental Health Perspectives, 2012, 120, 601-607.	6.0	186
27	Recreational Use of Mephedrone (4-Methylmethcathinone, 4-MMC) with Associated Sympathomimetic Toxicity. Journal of Medical Toxicology, 2010, 6, 327-330.	1.5	185
28	The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal, 2011, 4, 7107.	3.0	157
29	The pharmacology and toxicology of the synthetic cathinone mephedrone (4â€methylmethcathinone). Drug Testing and Analysis, 2011, 3, 454-463.	2.6	139
30	The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation "legal highs―in South London gay dance clubs. Journal of Substance Use, 2011, 16, 263-272.	0.7	134
31	Extracorporeal Treatment for Lithium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 875-887.	4.5	128
32	Do Novel Psychoactive Substances Displace Established Club Drugs, Supplement Them or Act as Drugs of Initiation The relationship between Mephedrone, Ecstasy and Cocaine. European Addiction Research, 2013, 19, 276-282.	2.4	119
33	Use of High-Resolution Accurate Mass Spectrometry to Detect Reported and Previously Unreported Cannabinomimetics in "Herbal High" Products. Journal of Analytical Toxicology, 2010, 34, 252-260.	2.8	117
34	Effect of the <scp>UK</scp> 's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. British Journal of Clinical Pharmacology, 2014, 78, 610-618.	2.4	110
35	â€~Our favourite drug': prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. Journal of Substance Use, 2012, 17, 91-97.	0.7	107
36	Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clinical Toxicology, 2015, 53, 893-900.	1.9	107

#	Article	IF	Citations
37	Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 2012, 68, 853-856.	1.9	106
38	The EXTRIP ( <i>EXtracorporeal TReatments In Poisoning</i> ) workgroup: Guideline methodology. Clinical Toxicology, 2012, 50, 403-413.	1.9	103
39	Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clinical Toxicology, 2015, 53, 54-59.	1.9	101
40	Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. The Lancet Gastroenterology and Hepatology, 2018, 3, 104-113.	8.1	99
41	Gadolinium deposition and the potential for toxicological sequelae – A literature review of issues surrounding gadoliniumâ€based contrast agents. British Journal of Clinical Pharmacology, 2018, 84, 2522-2534.	2.4	99
42	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine, 2015, 66, 165-181.	0.6	98
43	Limited use of novel psychoactive substances in South London nightclubs. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 959-964.	0.5	96
44	Prescription opioid abuse in the <scp>UK</scp> . British Journal of Clinical Pharmacology, 2013, 76, 823-824.	2.4	92
45	Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clinical Toxicology, 2015, 53, 85-92.	1.9	83
46	Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 527-529.	0.5	82
47	Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. Postgraduate Medical Journal, 2014, 90, 133-138.	1.8	80
48	Misuse of the γâ€aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. British Journal of Clinical Pharmacology, 2014, 78, 190-191.	2.4	79
49	Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation. Clinical Toxicology, 2012, 50, 438-440.	1.9	76
50	What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient?. Clinical Toxicology, 2015, 53, 145-150.	1.9	76
51	Misuse of benzodiazepines and Z-drugs in the UK. British Journal of Psychiatry, 2014, 205, 407-408.	2.8	72
52	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019. Lancet Regional Health - Europe, The, 2022, 16, 100341.	5.6	70
53	Acute toxicity and withdrawal syndromes related to gammaâ€hydroxybutyrate (GHB) and its analogues gammaâ€butyrolactone (GBL) and 1,4â€butanediol (1,4â€BD). Drug Testing and Analysis, 2011, 3, 417-425.	2.6	68
54	Guidelines for Reporting Case Studies on Extracorporeal Treatments in Poisonings: Methodology. Seminars in Dialysis, 2014, 27, 407-414.	1.3	68

#	Article	IF	CITATIONS
55	Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry, 2016, 16, 293.	2.6	68
56	First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology, 2013, 69, 373-376.	1.9	66
57	Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicology Letters, 2017, 277, 84-91.	0.8	64
58	The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in †Spiceâ€. International Journal of Drug Policy, 2011, 22, 274-277.	3.3	62
59	Novel Psychoactive Substances. Therapeutic Drug Monitoring, 2012, 34, 363-367.	2.0	62
60	Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 227-233.	4.8	62
61	Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 147-152.	0.5	59
62	Outcomes from massive paracetamol overdose: a retrospective observational study. British Journal of Clinical Pharmacology, 2017, 83, 1263-1272.	2.4	59
63	Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). Journal of Medical Toxicology, 2008, 4, 254-257.	1.5	58
64	Collapse, reported seizure—and an unexpected pill. Lancet, The, 2007, 369, 1490.	13.7	56
65	Challenges in the diagnosis of ethylene glycol poisoning. Annals of Clinical Biochemistry, 2014, 51, 167-178.	1.6	56
66	Epidemiology of Recreational Drug Toxicity in a Nightclub Environment. Substance Use and Misuse, 2009, 44, 1495-1502.	1.4	55
67	Epidemiology of adolescent substance use in London schools. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 405-409.	0.5	55
68	Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. Drug Testing and Analysis, 2014, 6, 506-515.	2.6	54
69	Presentations to the Emergency Department Following Cannabis use—a Multi-Centre Case Series from Ten European Countries. Journal of Medical Toxicology, 2015, 11, 415-421.	1.5	54
70	Poisoned patients as potential organ donors: postal survey of transplant centres and intensive care units. Critical Care, 2003, 7, 147.	5.8	53
71	A cloud on the horizon–a survey into the use of electronic vaping devices for recreational drug and new psychoactive substance (NPS) administration. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 9-14.	0.5	50
72	Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clinical Toxicology, 2017, 55, 338-345.	1.9	49

#	Article	IF	Citations
73	Understanding How Data Triangulation Identifies Acute Toxicity of Novel Psychoactive Drugs. Journal of Medical Toxicology, 2012, 8, 300-303.	1.5	47
74	Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials, 2016, 17, 472.	1.6	45
75	Association of Blood Lead Level with Neurological Features in 972 Children Affected by an Acute Severe Lead Poisoning Outbreak in Zamfara State, Northern Nigeria. PLoS ONE, 2014, 9, e93716.	2.5	45
76	Recreational Drug Use in the Asia Pacific Region: Improvement in Our Understanding of the Problem Through the UNODC Programmes. Journal of Medical Toxicology, 2012, 8, 295-299.	1.5	44
77	Phenibut (4â€aminoâ€3â€phenylâ€butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug and Alcohol Review, 2016, 35, 591-596.	2.1	44
78	Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. EClinicalMedicine, 2019, 11, 11-17.	7.1	44
79	Acute Psychosis Associated with Recreational Use of Benzofuran 6-(2-Aminopropyl)Benzofuran (6-APB) and Cannabis. Journal of Medical Toxicology, 2013, 9, 278-281.	1.5	43
80	Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. European Journal of Emergency Medicine, 2013, 20, 263-267.	1.1	43
81	Extracorporeal Treatment for Thallium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1682-1690.	4.5	41
82	Current European data collection on emergency department presentations with acute recreational drug toxicity: Gaps and national variations. Clinical Toxicology, 2014, 52, 1005-1012.	1.9	40
83	Description of 3,180 Courses of Chelation with Dimercaptosuccinic Acid in Children ≧ y with Severe Lead Poisoning in Zamfara, Northern Nigeria: A Retrospective Analysis of Programme Data. PLoS Medicine, 2014, 11, e1001739.	8.4	39
84	Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?. Open Access Emergency Medicine, 2011, 3, 69.	1.3	34
85	Risk of caffeine toxicity associated with the use of †legal highs' (novel psychoactive substances). European Journal of Clinical Pharmacology, 2012, 68, 435-439.	1.9	34
86	National audit of antidote stocking in acute hospitals in the UK. Emergency Medicine Journal, 2013, 30, 393-396.	1.0	32
87	Polonium-210 poisoning: a first-hand account. Lancet, The, 2016, 388, 1075-1080.	13.7	32
88	Gadolinium-based contrast agents – what is the evidence for â€~gadolinium deposition disease' and the use of chelation therapy?. Clinical Toxicology, 2020, 58, 151-160.	1.9	32
89	ICD-10 coding: poor identification of recreational drug presentations to a large emergency department. Emergency Medicine Journal, 2011, 28, 387-389.	1.0	31
90	Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emergency Medicine Journal, 2013, 30, 70-71.	1.0	31

#	Article	IF	Citations
91	Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Testing and Analysis, 2014, 6, 850-860.	2.6	31
92	Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation. Journal of Medical Toxicology, 2016, 12, 396-401.	1.5	31
93	Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set. NeuroToxicology, 2019, 73, 183-187.	3.0	31
94	Detection of mephedrone and its metabolites in fingerprints from a controlled human administration study by liquid chromatography-tandem mass spectrometry and paper spray-mass spectrometry. Analyst, The, 2020, 145, 3038-3048.	3.5	30
95	Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). Journal of Medical Toxicology, 2008, 4, 167-169.	1.5	29
96	External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose. Clinical Toxicology, 2015, 53, 807-814.	1.9	29
97	Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances—Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam—in the UK. Journal of Medical Toxicology, 2018, 14, 134-143.	1.5	29
98	Acute recreational drug toxicity. Medicine (United States), 2018, 97, e9784.	1.0	29
99	Consensus statements on the approach to patients in a methanol poisoning outbreak. Clinical Toxicology, 2019, 57, 1129-1136.	1.9	29
100	Running an unknown risk: a marathon death associated with the use of 1,3â€dimethylamylamine (DMAA). Drug Testing and Analysis, 2015, 7, 433-438.	2.6	28
101	Should a Lower Treatment Line Be Used When Treating Paracetamol Poisoning in Patients with Chronic Alcoholism?. Drug Safety, 2002, 25, 625-632.	3.2	27
102	Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clinical Toxicology, 2012, 50, 727-732.	1.9	27
103	Acute Toxicity Associated with Analytically Confirmed Recreational use of Methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). Journal of Medical Toxicology, 2014, 10, 299-302.	1.5	27
104	Analysis of anonymized pooled urine in nine UK cities: variation in classical recreational drug, novel psychoactive substance and anabolic steroid use. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 929-933.	0.5	27
105	The dark cloud of recreational drugs and vaping. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 145-148.	0.5	25
106	Epidemiology, clinical features and management of patients presenting to European emergency departments with acute cocaine toxicity: comparison between powder cocaine and crack cocaine cases. Clinical Toxicology, 2019, 57, 718-726.	1.9	25
107	Circulating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury. Clinical Pharmacology and Therapeutics, 2017, 101, 531-540.	4.7	24
108	Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication. Toxicology Letters, 2019, 314, 37-42.	0.8	24

#	Article	IF	CITATIONS
109	First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. European Journal of Emergency Medicine, 2008, 15, 354-356.	1.1	23
110	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification. Clinical Chemistry, 2018, 64, 346-354.	3.2	23
111	Detection of the pharmaceutical agent glaucine as a recreational drug. European Journal of Clinical Pharmacology, 2008, 64, 553-554.	1.9	22
112	Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. European Journal of Clinical Pharmacology, 2015, 71, 1185-1196.	1.9	22
113	Delays during the administration of acetylcysteine for the treatment of paracetamol overdose. British Journal of Clinical Pharmacology, 2016, 82, 1358-1363.	2.4	22
114	Significant Misuse of Sildenafil in London Nightclubs. Substance Use and Misuse, 2015, 50, 1390-1394.	1.4	21
115	Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: profiling and relation to sales data. European Journal of Clinical Pharmacology, 2019, 75, 77-85.	1.9	21
116	A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose. Open Access Emergency Medicine, 2011, 3, 87.	1.3	20
117	A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. European Journal of Clinical Pharmacology, 2012, 68, 349-353.	1.9	20
118	Metal-on-Metal Hip Joint Prostheses: a Retrospective Case Series Investigating the Association of Systemic Toxicity with Serum Cobalt and Chromium Concentrations. Journal of Medical Toxicology, 2017, 13, 321-328.	1.5	20
119	First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. European Journal of Clinical Pharmacology, 2013, 69, 361-363.	1.9	18
120	Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act. Clinical Toxicology, 2019, 57, 36-41.	1.9	18
121	Poor Identification of Emergency Department Acute Recreational Drug Toxicity Presentations Using Routine Hospital Coding Systems: the Experience in Denmark, Switzerland and the UK. Journal of Medical Toxicology, 2019, 15, 112-120.	1.5	18
122	Synthetic cannabinoid availability on darknet drug marketsâ€"changes during 2016â€"2017. Toxicology Communications, 2019, 3, 7-15.	0.7	18
123	Severe Toxicity to the New Psychoactive Substances 3-Hydroxyphencyclidine and N-Ethylhexedrone: an Analytically Confirmed Case Report. Journal of Medical Toxicology, 2020, 16, 67-70.	1.5	18
124	Monitoring trends in recreational drug use from the analysis of the contents of amnesty bins in gay dance clubs. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 1111-1117.	0.5	17
125	Prevalence of Use of Electronic Nicotine Delivery Systems (ENDS) to Vape Recreational Drugs by Club Patrons in South London. Journal of Medical Toxicology, 2017, 13, 61-65.	1.5	17
126	Incidence and management of N-acetylcysteine-related anaphylactoid reactions during the management of acute paracetamol overdose. European Journal of Emergency Medicine, 2013, 21, 1.	1.1	16

#	Article	IF	CITATIONS
127	Using Internet Snapshot Surveys to Enhance Our Understanding of the Availability of the Novel Psychoactive Substance 4-Methylaminorex and 4,4′-Dimethylaminorex. Journal of Medical Toxicology, 2015, 11, 80-84.	1.5	16
128	Stability of mephedrone and five of its phase I metabolites in human whole blood. Drug Testing and Analysis, 2019, 11, 586-594.	2.6	16
129	Quantification of cocaine and cocaine metabolites in dried blood spots from a controlled administration study using liquid chromatography–tandem mass spectrometry. Drug Testing and Analysis, 2019, 11, 709-720.	2.6	16
130	Paracetamol toxicity: what would be the implications of a change in UK treatment guidelines?. European Journal of Clinical Pharmacology, 2012, 68, 1541-1547.	1.9	15
131	Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments. Clinical Toxicology, 2021, 59, 896-904.	1.9	15
132	Recreational drug use presentations during a large outdoor festival event: Reduction in hospital emergency department transfer where medical physicians are present. Journal of Substance Use, 2010, 15, 434-441.	0.7	14
133	The Global Educational Toxicology Uniting Project (GETUP): an Analysis of the First Year of a Novel Toxicology Education Project. Journal of Medical Toxicology, 2015, 11, 295-300.	1.5	14
134	Nopaine no gain: Recreational ethylphenidate toxicity. Clinical Toxicology, 2015, 53, 498-499.	1.9	14
135	4â€Methylâ€5â€(4â€methylphenyl)â€4,5â€dihydrooxazolâ€2â€amine (4,4′â€DMAR, 4,4′â€dimethylam prevalence of use, desired effects and acute toxicity. Human Psychopharmacology, 2015, 30, 193-198.	inorex); avai	labjlity,
136	A comparison of recreational drug use amongst sexual health clinic users in London with existing prevalence data. International Journal of STD and AIDS, 2016, 27, 1309-1316.	1.1	14
137	The Availability of Modafinil and Methylphenidate Purchased from the Internet in the United Kingdom Without a Prescription. Substance Use and Misuse, 2020, 55, 56-65.	1.4	14
138	Evaluation of longâ€term detection trends of new psychoactive substances in pooled urine from city street portable urinals (London, UK). British Journal of Clinical Pharmacology, 2020, 86, 517-527.	2.4	14
139	Nonmedical use of benzodiazepines and Zâ€drugs in the UK. British Journal of Clinical Pharmacology, 2021, 87, 1676-1683.	2.4	14
140	Do capillary dried blood spot concentrations of gammaâ€hydroxybutyric acid mirror those in venous blood? A comparative study. Drug Testing and Analysis, 2015, 7, 336-340.	2.6	13
141	An assessment of the variation in the concentration of acetylcysteine in infusions for the treatment of paracetamol overdose. British Journal of Clinical Pharmacology, 2017, 83, 393-399.	2.4	13
142	Validation of Activity-Based Screening for Synthetic Cannabinoid Receptor Agonists in a Large Set of Serum Samples. Clinical Chemistry, 2019, 65, 347-349.	3.2	13
143	Improvement in the pre-hospital care of recreational drug users through the development of club specific ambulance referral guidelines. Substance Abuse Treatment, Prevention, and Policy, 2008, 3, 14.	2.2	12
144	Intravenous fluid use in the acutely unwell adult medical inpatient: improving practice through a clinical audit process. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 211-215.	0.6	12

#	Article	IF	CITATIONS
145	Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.		12
146	Using Drug-Intoxicated Deaths as Potential Organ Donors: Impression of Attendees at the American College of Medical Toxicology 2014 Annual Scientific Meeting. Journal of Medical Toxicology, 2014, 10, 360-363.	1.5	12
147	Microwave-assisted on-spot derivatization for gas chromatography–mass spectrometry based determination of polar low molecular weight compounds in dried blood spots. Journal of Chromatography A, 2016, 1465, 175-183.	3.7	12
148	Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability. European Journal of Clinical Pharmacology, 2018, 74, 349-356.	1.9	12
149	Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study. Clinical Toxicology, 2019, 57, 663-667.	1.9	12
150	MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014–2017. Clinical Toxicology, 2021, 59, 131-137.	1.9	12
151	Analysis of Urine from Pooled Urinals - A Novel Method for the Detection of Novel Psychoactive Substances. Current Drug Abuse Reviews, 2014, 6, 86-90.	3.4	12
152	Epidemiology of Recreational Drug Toxicity in a Nightclub Environment., 2009, 44, 1495-1502.		11
153	Using Internet Snapshot Surveys to Enhance Our Understanding of the Availability of the Novel Psychoactive Substance Alpha-methyltryptamine (AMT). Substance Use and Misuse, 2014, 49, 7-12.	1.4	11
154	The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 619-622.	0.5	11
155	Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital. International Journal of Psychiatry in Clinical Practice, 2013, 17, 154-156.	2.4	10
156	Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. Reanimation: Journal De La Societe De Reanimation De Langue Française, 2015, 24, 527-541.	0.1	10
157	Management of body stuffers presenting to the emergency department. European Journal of Emergency Medicine, 2016, 23, 425-429.	1.1	10
158	Activated charcoal significantly reduces the amount of colchicine released from <i>Gloriosa superba </i> ii> in simulated gastric and intestinal media. Clinical Toxicology, 2017, 55, 914-918.	1.9	10
159	Concurrent Use of Benzodiazepine by Heroin Users—What Are the Prevalence and the Risks Associated with This Pattern of Use?. Journal of Medical Toxicology, 2019, 15, 4-11.	1.5	10
160	Rhabdomyolysis related to acute recreational drug toxicityâ€"A Euro-DEN study. PLoS ONE, 2021, 16, e0246297.	2.5	10
161	Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. Frontiers in Psychiatry, 2021, 12, 676224.	2.6	10
162	Analysis of recreational drug samples obtained from patients presenting to a busy inner-city emergency department: a pilot study adding to knowledge on local recreational drug use. Emergency Medicine Journal, 2011, 28, 11-13.	1.0	9

#	Article	IF	Citations
163	Patterns of Acute Toxicity Associated with New Psychoactive Substances. Handbook of Experimental Pharmacology, 2018, 252, 475-494.	1.8	9
164	Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. Drug Testing and Analysis, 2019, 11, 1419-1430.	2.6	9
165	Acute toxicity related to misuse (nonmedical use) of tramadol: Experience of the European Drug Emergencies Network Plus. British Journal of Clinical Pharmacology, 2021, 87, 1668-1675.	2.4	9
166	Novel drugsnovel branding. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1125-1126.	0.5	8
167	Internet survey of home storage of paracetamol by individuals in the UK. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 253-259.	0.5	8
168	Determining the volume of toxic liquid ingestions in adults: accuracy of estimates by healthcare professionals and members of the public. Clinical Toxicology, 2013, 51, 77-82.	1.9	8
169	Lesson of the month 1: Acute flecainide overdose and the potential utility of lipid emulsion therapy. Clinical Medicine, 2015, 15, 301-303.	1.9	8
170	MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance. Substance Use and Misuse, 2017, 52, 223-232.	1.4	8
171	UK survey of non-medical use of prescription drugs (NMURx) as a valuable source of general population illicit drug use data. Postgraduate Medical Journal, 2018, 94, 627-633.	1.8	8
172	Pesticide-Poisoned Patients: Can They Be Used as Potential Organ Donors?. Journal of Medical Toxicology, 2018, 14, 278-282.	1.5	8
173	Nonmedical use of alprazolam in the UK: Results from a nationally representative survey. British Journal of Clinical Pharmacology, 2019, 85, 1841-1845.	2.4	8
174	Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. Journal of Analytical Toxicology, 2021, 45, 730-738.	2.8	8
175	Doctors and Nurses Estimation of the Weight of Patients: A Preventable Source of Systematic Error. Journal of Toxicology: Clinical Toxicology, 2004, 42, 611-615.	1.5	7
176	Clinical survey assessing the appropriate management of individuals with acute recreational drug toxicity at a large outdoor festival event. Journal of Substance Use, 2012, 17, 356-362.	0.7	7
177	Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. Journal of Clinical Sleep Medicine, 2016, 12, 1499-1505.	2.6	7
178	Establishing Reference Intervals for Gadolinium Concentrations in Blood, Plasma, and Urine in Individuals Not Previously Exposed to Gadolinium-Based Contrast Agents. Investigative Radiology, 2020, 55, 405-411.	6.2	7
179	Prescription medicine misuse in the Asia–Pacific region: An evolving issue?. British Journal of Clinical Pharmacology, 2021, 87, 1660-1667.	2.4	7
180	Regional, national and international datasets: How they improve our understanding of the acute harms associated with prescription medicine misuse. British Journal of Clinical Pharmacology, 2021, 87, 1654-1659.	2.4	7

#	Article	IF	CITATIONS
181	Nonâ€medical use of benzodiazepines and GABA analogues in Europe. British Journal of Clinical Pharmacology, 2021, 87, 1684-1694.	2.4	7
182	Lead poisoning among asymptomatic individuals with a long-term history of opiate use in Golestan Cohort Study. International Journal of Drug Policy, 2022, 104, 103695.	3.3	7
183	Synthetic Amphetamine Derivatives. , 2013, , 161-178.		6
184	Problematic recreational drug use: is there a role for outpatient sexual health clinics in identifying those not already engaged with treatment services?. Sexual Health, 2015, 12, 501.	0.9	6
185	Epidemiology, toxicokinetics and biomarkers after self-poisoning with <i>Gloriosa superba</i> Clinical Toxicology, 2019, 57, 1080-1086.	1.9	6
186	Cold water extraction of codeine/paracetamol combination products: a case series and literature review. Clinical Toxicology, 2020, 58, 107-111.	1.9	6
187	Gadolinium Concentrations in Biological Matrices From Patients Exposed to Gadolinium-Based Contrast Agents. Investigative Radiology, 2021, Publish Ahead of Print, 458-464.	6.2	6
188	Pharmacokinetics of Mephedrone Enantiomers in Whole Blood after a Controlled Intranasal Administration to Healthy Human Volunteers. Pharmaceuticals, 2021, 14, 5.	3.8	6
189	Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 115-119.	0.5	6
190	Reported ingested dose of paracetamol as a predictor of risk following paracetamol overdose. European Journal of Clinical Pharmacology, 2014, 70, 1513-1518.	1.9	5
191	Taking stock: UK national antidote availability increasing, but further improvements are required. European Journal of Hospital Pharmacy, 2016, 23, 145-150.	1.1	5
192	Misuse of prescription and over-the-counter medicines in South London nightclubs. Journal of Substance Use, 2016, 21, 495-500.	0.7	5
193	An evaluation of the role of mixing techniques in the observed variation in acetylcysteine infusion concentrations. British Journal of Clinical Pharmacology, 2019, 85, 252-257.	2.4	5
194	Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact. Forensic Toxicology, 2020, 38, 95-107.	2.4	5
195	Acute toxicity from the synthetic cathinone <i>N</i> -ethylpentylone (ephylone) in the United Kingdom. Clinical Toxicology, 2021, 59, 1270-1273.	1.9	5
196	National audit of antidote stocking in UK emergency departments. European Journal of Hospital Pharmacy, 2021, 28, 217-222.	1.1	5
197	Machine Learning to Assist in Large-Scale, Activity-Based Synthetic Cannabinoid Receptor Agonist Screening of Serum Samples. Clinical Chemistry, 2022, 68, 906-916.	3 <b>.</b> 2	5
198	The association between the availability of over the counter codeine and the prevalence of non-medical use. European Journal of Clinical Pharmacology, 2022, 78, 1011-1018.	1.9	5

#	Article	IF	CITATIONS
199	Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act. Addiction, 2022, 117, 2899-2906.	3.3	5
200	Dissemination and uptake of a new treatment pathway for paracetamol poisoning in the UK: a survey of healthcare professionals. British Journal of Clinical Pharmacology, 2013, 76, 946-950.	2.4	4
201	Chronic Ayurvedic medicine use associated with major and fatal congenital abnormalities. Medical Journal of Australia, 2015, 203, 443-444.	1.7	4
202	Availability of prescription zopiclone over the internet. BMJ, The, 2015, 351, h5710.	6.0	4
203	Corrosives. Medicine, 2016, 44, 153-156.	0.4	4
204	Review of European-Drug Emergencies Network (Euro-DEN) training package for non-specialist workers to assess acute recreational drug and new psychoactive substance toxicity in night-time economy environments. Drugs: Education, Prevention and Policy, 2016, 23, 73-77.	1.3	4
205	An evaluation of online discussion relating to nonmedical use of prescription opioids within the UK. British Journal of Clinical Pharmacology, 2021, 87, 1637-1646.	2.4	4
206	Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex. Clinical Toxicology, 2022, 60, 912-919.	1.9	4
207	Perceived risk of using novel psychoactive substances in school students: lower in users compared to non-users. Journal of Substance Use, 2016, 21, 323-326.	0.7	3
208	Better data, better policy and better lives: a call for improved drug monitoring and concerted responses. Addiction, 2020, 115, 199-200.	3.3	3
209	Impact of pregabalin co-use in patients presenting with acute heroin toxicity to the European Drug Emergencies Network Plus project. European Journal of Emergency Medicine, 2021, 28, 144-146.	1.1	3
210	Ethnic Differences in Self-Poisoning Across South London. Crisis, 2014, 35, 268-272.	1.2	3
211	Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers. Drug Testing and Analysis, 2022, 14, 741-746.	2.6	3
212	Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs. European Journal of Emergency Medicine, 2022, 29, 291-300.	1.1	3
213	Management of acute paracetamol (acetaminophen) toxicity: a standardised proforma improves risk assessment and overall risk stratification by emergency medicine doctors. Emergency Medicine Journal, 2012, 29, 961-964.	1.0	2
214	Mephedrone., 2013,, 211-231.		2
215	Development of a †patient information leaflet†for use following assessment of patients with reported or suspected paracetamol overdose in the UK. Pharmacology Research and Perspectives, 2014, 2, e00075.	2.4	2

Novel psychoactive substances or â€legal highs'. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0.0 rgBT /Qverlock 10

#	Article	IF	CITATIONS
217	Assessing the effect of extracorporeal treatments for lithium poisoning. British Journal of Clinical Pharmacology, 2021, 87, 214-215.	2.4	2
218	Emergencies related to recreational drug abuse in Spain compared to emergencies attended in 3 European areas. Emergencias, 2018, 30, 385-394.	0.6	2
219	From the internet to the hospital: current experiences of individuals presenting to the Emergency Department with acute recreational drug toxicity. Journal of Substance Use, 2014, , 1-4.	0.7	1
220	The toxicity of paracetamol–codeine combination in overdose is an unresolved issue. British Journal of Clinical Pharmacology, 2018, 84, 806-807.	2.4	1
221	The challenge of the novel psychoactive substances: How have we responded and what are the implications of this response?. British Journal of Clinical Pharmacology, 2020, 86, 407-409.	2.4	1
222	Paracetamol toxicity in mild overdose in combination with opioids: A retrospective observational study. British Journal of Clinical Pharmacology, 2022, 88, 1258-1267.	2.4	1
223	Synthetic cathinones., 2022,, 333-380.		1
224	Arylcyclohexamines: Ketamine, Phencyclidine, and Analogues., 2017, , 1439-1484.		1
225	Using Journal Review Articles to Increase the Dissemination of Keynote and Symposia Lectures at International Medical Congresses. Journal of Medical Toxicology, 2012, 8, 250-251.	1.5	0
226	Limited evidence for the safety of $\hat{l}^2$ -blockers for cocaine-associated chest pain. American Journal of Emergency Medicine, 2013, 31, 988-989.	1.6	0
227	Response to Letter to the Editor: External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose. Clinical Toxicology, 2015, 53, 1154-1154.	1.9	0
228	Letter in reply to Riggan et al. Re: External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose. Clinical Toxicology, 2015, 53, 1157-1157.	1.9	0
229	Response to the letter from Wong et al EClinicalMedicine, 2019, 14, 13.	7.1	0
230	Authors' reply to comment on "Epidemiology, clinical features and management of patients presenting to European emergency departments with acute cocaine toxicity: comparison between powder cocaine and crack cocaine cases― Clinical Toxicology, 2020, 58, 72-74.	1.9	0
231	Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues). , 2016, , 1-46.		0
232	Arylcyclohexamines: Ketamine, Phencyclidine, and Analogues., 2018,, 1-47.		0
233	Acute recreational drug toxicity - poor identification of Emergency Department presentations in Europe using routine hospital coding systems. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-9-27.	0.0	0
234	A Sentinel and Design Model of Evidence Collection on Acute Drug and NPS Toxicity., 2018, , 114-131.		0

#	Article	lF	CITATIONS
235	Online availability of gabapentin and pregabalin and the impact of legal reclassification in the United Kingdom. Drugs: Education, Prevention and Policy, $0$ , $1$ - $5$ .	1.3	O